One of the main goals of Life4me+ — is to prevent new cases of HIV and other STIs, hepatitis C and tuberculosis.

The app helps to establish anonym communication between physicians and HIV-positive people. It allows you to conveniently organize your medication intake timetable and set concealed and personalized reminders.

All news

Archive

✕

13 December 2018

6511

PEPFAR Program to Fight HIV/AIDS will be extended

PEPFAR Program to Fight HIV/AIDS will be extended

On Tuesday, 11 Dec., Washington was unanimously adopted by Congress and signed by US President Donald Trump to extend the country's largest program to combat HIV / AIDS PEPFAR.

11 December 2018

6794

Sixth case of HIV transmission to person taking PrEP

Sixth case of HIV transmission to person taking PrEP

In the United States, the sixth case of HIV transmission to a person with a high degree of adherence to pre-exposure prophylaxis (PrEP) has been reported. According to a report published this week in Lancet magazine, a 21-year-old Latin American from San Francisco test tested ...

7 December 2018

6933

European activists demanded that EPO withdraw Gilead's patent for sofosbuvir

European activists demanded that EPO withdraw Gilead's patent for sofosbuvir

Six nongovernmental organizations this week appealed the September decision of the European Patent Office (EPO) support a patent for the pharmaceutical company Gilead Sciences for a key drug for the treatment of hepatitis C sofosbuvir.

4 December 2018

6949

BHIVA: “Undeterminable workload - zero risk of HIV transmission”

BHIVA: “Undeterminable workload - zero risk of HIV transmission”

The British HIV Association (BHIVA) has called for the rejection of “misleading” statements about the “minimal” or “minor” risk of HIV transmission when it comes to undetectable viral load. The principle "undetectable = untransmittable" does not allow for inaccuracies in ...

22 November 2018

7187

Minsk signed the Paris Declaration on accelerating measures to end the AIDS epidemic

Minsk signed the Paris Declaration on accelerating measures to end the AIDS epidemic

On the third day of the II Regional Meeting on expanding access to high-quality and affordable drugs and diagnostic products for treating and preventing HIV in the EECA countries, Minsk supported the Paris Declaration on Accelerating Action to End the AIDS Epidemic in Large ...

19 October 2018

7798

Gilead and Aelix join forces to develop a promising anti-HIV combination

Gilead and Aelix join forces to develop a promising anti-HIV combination

American pharmaceutical company Gilead Sciences - the world leader in the development of drugs for the treatment of HIV and hepatitis C - has teamed up with the Spanish Aelix Therapeutics in order to develop a fundamentally new ART-regimen, according to PMLive.

18 October 2018

7965

IDWeek-2018 presented new data confirming the long-term effectiveness of ART-schemes “in one pill”

IDWeek-2018 presented new data confirming the long-term effectiveness of ART-schemes “in one pill”

According to a number of studies presented at the IDWeek-2018 conference in San Francisco, several newest ART-schemes “in one pill” are capable of supporting an undetectable burden of HIV for two years or more.

17 October 2018

6648

Spanish scientists told about promising results of HIV suppression in stem cell transplantation

Spanish scientists told about promising results of HIV suppression in stem cell transplantation

A group of researchers from the Madrid Hospital. Gregorio Maranyon and the IrsiCaixa HIV Research Institute of Barcelona last Tuesday reported on the impressive results of suppressing HIV-positive patients with virus strains in hidden reservoirs thanks to the stem cell transplant ...

15 October 2018

6115

American patients admitted that they are not ready to switch to new ways of ART delivery

American patients admitted that they are not ready to switch to new ways of ART delivery

According to a US study published in Open Forum Infectious Diseases, two-thirds of people taking combined antiretroviral therapy (ART) will be interested in switching to the oral regimen once a week. The idea of switching to long-term injection therapy is supported by less ...

26 September 2018

6743

Immunotherapy of HIV passed the first phase of clinical trials

Immunotherapy of HIV passed the first phase of clinical trials

Preliminary results from phase I clinical trials demonstrated the safety and tolerability of cell therapy, including the introduction of artificially expanded T-cells with widely neutralizing antibodies (bNAbs) into the blood of HIV-positive volunteers who had previously ...

1...30 31 32 33 34...116